Acetylcholinesterase: Difference between revisions

Jump to navigation Jump to search
m (Bot: HTTP→HTTPS (v475))
 
imported>Funkyman99
m (→‎Inhibitors: fixed spelling)
 
Line 1: Line 1:
{{Short description|A gene or the protein it encodes in various Animalia including humans}}
{{Redirect|ACHE||Ache (disambiguation){{!}}Ache}}
{{Redirect|ACHE||Ache (disambiguation){{!}}Ache}}
{{enzyme
{{enzyme
Line 11: Line 12:
}}
}}
{{Infobox_gene}}
{{Infobox_gene}}
'''Acetylcholinesterase''' ([[HUGO Gene Nomenclature Committee|HGNC]] symbol '''ACHE'''), also known as '''AChE''' or '''acetylhydrolase''', is the primary [[cholinesterase]] in the body. It is an [[enzyme]] that [[catalysis|catalyzes]] the breakdown of [[acetylcholine]] and of some other [[choline]] esters that function as [[neurotransmitter]]s. AChE is found at mainly [[neuromuscular junction]]s and in [[chemical synapse]]s of the [[cholinergic]] type, where its activity serves to terminate [[neurotransmission|synaptic transmission]]. It belongs to [[carboxylesterase family]] of enzymes. It is the primary target of inhibition by [[organophosphorus]] compounds such as [[nerve agents]] and [[pesticides]].
 
'''Acetylcholinesterase''' ([[HUGO Gene Nomenclature Committee|HGNC]] symbol '''ACHE'''; EC 3.1.1.7), also known as '''AChE''' or '''acetylhydrolase''', is the primary [[cholinesterase]] in the body. It is an [[enzyme]] that [[catalysis|catalyzes]] the breakdown of [[acetylcholine]] and of some other [[choline]] esters that function as [[neurotransmitter]]s. AChE is found at mainly [[neuromuscular junction]]s and in [[chemical synapse]]s of the [[cholinergic]] type, where its activity serves to terminate [[neurotransmission|synaptic transmission]]. It belongs to [[carboxylesterase family]] of enzymes. It is the primary target of inhibition by [[organophosphorus]] compounds such as [[nerve agents]] and [[pesticides]].


==Enzyme structure and mechanism==
==Enzyme structure and mechanism==
[[File:AChe mechanism of action.jpg|thumb|left|AChe mechanism of action<ref>{{cite book | vauthors = Katzung BG | title = Basic and clinical pharmacology:Introduction to autonomic pharmacology | year = 2001 | publisher = The McGraw Hill Companies | isbn = 978-0-07-160405-5 | pages = 75–91 | edition = 8 }}</ref>]]
[[File:AChe mechanism of action.jpg|thumb|left|AChe mechanism of action<ref>{{cite book | vauthors = Katzung BG | title = Basic and clinical pharmacology:Introduction to autonomic pharmacology | year = 2001 | publisher = The McGraw Hill Companies | isbn = 978-0-07-160405-5 | pages = 75–91 | edition = 8 }}</ref>]]


AChE is a [[hydrolase]] that [[hydrolyzes]] choline esters. It has a very high [[catalytic]] activity - each molecule of AChE degrades about 25000 molecules of [[acetylcholine]] (ACh) per second, approaching the limit allowed by [[diffusion]] of the [[Enzyme substrate (biology)|substrate]].<ref name = "Quinn_1987">{{cite journal | vauthors = Quinn DM | title = Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states | journal = Chemical Reviews | volume = 87 | issue =  5| pages = 955–79 | year = 1987 | pmid =  | doi = 10.1021/cr00081a005 }}</ref><ref>{{cite journal | vauthors = Taylor P, Radić Z | title = The cholinesterases: from genes to proteins | journal = Annual Review of Pharmacology and Toxicology | volume = 34 | issue =  | pages = 281–320 | year = 1994 | pmid = 8042853 | doi = 10.1146/annurev.pa.34.040194.001433 }}</ref> The [[active site]] of AChE comprises 2 subsites  -  the anionic site and the esteratic subsite.  The structure and mechanism of action of AChE have been elucidated from the crystal structure of the enzyme.<ref name="pmid1678899">{{cite journal | vauthors = Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I | title = Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein | journal = Science | volume = 253 | issue = 5022 | pages = 872–9 | date = August 1991 | pmid = 1678899 | doi = 10.1126/science.1678899 | bibcode = 1991Sci...253..872S }}</ref><ref name="pmid8343975">{{cite journal | vauthors = Sussman JL, Harel M, Silman I | title = Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs | journal = Chem. Biol. Interact. | volume = 87 | issue = 1–3 | pages = 187–97 | date = June 1993 | pmid = 8343975 | doi = 10.1016/0009-2797(93)90042-W }}</ref>
AChE is a [[hydrolase]] that [[hydrolyzes]] choline esters. It has a very high [[catalytic]] activity—each molecule of AChE degrades about 25000 molecules of [[acetylcholine]] (ACh) per second, approaching the limit allowed by [[diffusion]] of the [[Enzyme substrate (biology)|substrate]].<ref name = "Quinn_1987">{{cite journal | vauthors = Quinn DM | title = Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states | journal = Chemical Reviews | volume = 87 | issue =  5| pages = 955–79 | year = 1987 | pmid =  | doi = 10.1021/cr00081a005 }}</ref><ref>{{cite journal | vauthors = Taylor P, Radić Z | title = The cholinesterases: from genes to proteins | journal = Annual Review of Pharmacology and Toxicology | volume = 34 | issue =  | pages = 281–320 | year = 1994 | pmid = 8042853 | doi = 10.1146/annurev.pa.34.040194.001433 }}</ref> The [[active site]] of AChE comprises 2 subsites—the anionic site and the esteratic subsite.  The structure and mechanism of action of AChE have been elucidated from the crystal structure of the enzyme.<ref name="pmid1678899">{{cite journal | vauthors = Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I | title = Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein | journal = Science | volume = 253 | issue = 5022 | pages = 872–9 | date = August 1991 | pmid = 1678899 | doi = 10.1126/science.1678899 | bibcode = 1991Sci...253..872S }}</ref><ref name="pmid8343975">{{cite journal | vauthors = Sussman JL, Harel M, Silman I | title = Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs | journal = Chem. Biol. Interact. | volume = 87 | issue = 1–3 | pages = 187–97 | date = June 1993 | pmid = 8343975 | doi = 10.1016/0009-2797(93)90042-W }}</ref>


The anionic subsite accommodates the positive quaternary [[amine]] of acetylcholine as well as other cationic substrates and [[Enzyme inhibitor|inhibitors]]. The cationic substrates are not bound by a negatively charged amino acid in the anionic site, but by interaction of 14 [[aromatic]] residues that line the gorge leading to the active site.<ref name="pmid1356436">{{cite journal | vauthors = Radić Z, Gibney G, Kawamoto S, MacPhee-Quigley K, Bongiorno C, Taylor P | title = Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants | journal = Biochemistry | volume = 31 | issue = 40 | pages = 9760–7 | date = October 1992 | pmid = 1356436 | doi = 10.1021/bi00155a032 }}</ref><ref name="pmid7836436">{{cite journal | vauthors = Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, Shafferman A | title = Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase | journal = J. Biol. Chem. | volume = 270 | issue = 5 | pages = 2082–91 | date = February 1995 | pmid = 7836436 | doi = 10.1074/jbc.270.5.2082 }}</ref><ref name="pmid9742217">{{cite journal | vauthors = Ariel N, Ordentlich A, Barak D, Bino T, Velan B, Shafferman A | title = The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors | journal = Biochem. J. | volume = 335 | issue = 1 | pages = 95–102 | date = October 1998 | pmid = 9742217 | pmc = 1219756 }} {{open access}}</ref> All 14 amino acids in the aromatic gorge are highly conserved across different species.<ref name="pmid8349597">{{cite journal | vauthors = Ordentlich A, Barak D, Kronman C, Flashner Y, Leitner M, Segall Y, Ariel N, Cohen S, Velan B, Shafferman A | title = Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket | journal = J. Biol. Chem. | volume = 268 | issue = 23 | pages = 17083–95 | date = August 1993 | pmid = 8349597 }} {{open access}}</ref> Among the aromatic amino acids, [[tryptophan]] 84 is critical and its substitution with [[alanine]] results in a 3000-fold decrease in reactivity.<ref>{{cite journal | vauthors = Tougu V | title = Acetylcholinesterase: Mechanism of Catalysis and Inhibition | journal = Current Medicinal Chemistry Central Nervous System Agents | volume = 1 | issue =  2| pages = 155–170 | year = 2001 | doi = 10.2174/1568015013358536 |url = https://www.researchgate.net/publication/233701777_Acetylcholinesterase_Mechanism_of_Catalysis_and_Inhibition/file/72e7e5163e39a2e539.pdf}} {{closed access}}</ref> The gorge penetrates halfway through the enzyme and is approximately 20 [[angstroms]] long.  The active site is located 4 angstroms from the bottom of the molecule.<ref>{{cite journal | vauthors = Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL | title = Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 90 | issue = 19 | pages = 9031–5 | year = 1993 | pmid = 8415649 | pmc = 47495 | doi = 10.1073/pnas.90.19.9031 | bibcode = 1993PNAS...90.9031H }}</ref>
The anionic subsite accommodates the positive quaternary [[amine]] of acetylcholine as well as other cationic substrates and [[Enzyme inhibitor|inhibitors]]. The cationic substrates are not bound by a negatively charged amino acid in the anionic site, but by interaction of 14 [[aromatic]] residues that line the gorge leading to the active site.<ref name="pmid1356436">{{cite journal | vauthors = Radić Z, Gibney G, Kawamoto S, MacPhee-Quigley K, Bongiorno C, Taylor P | title = Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants | journal = Biochemistry | volume = 31 | issue = 40 | pages = 9760–7 | date = October 1992 | pmid = 1356436 | doi = 10.1021/bi00155a032 }}</ref><ref name="pmid7836436">{{cite journal | vauthors = Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, Shafferman A | title = Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase | journal = J. Biol. Chem. | volume = 270 | issue = 5 | pages = 2082–91 | date = February 1995 | pmid = 7836436 | doi = 10.1074/jbc.270.5.2082 }}</ref><ref name="pmid9742217">{{cite journal | vauthors = Ariel N, Ordentlich A, Barak D, Bino T, Velan B, Shafferman A | title = The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors | journal = Biochem. J. | volume = 335 | issue = 1 | pages = 95–102 | date = October 1998 | pmid = 9742217 | pmc = 1219756 }} {{open access}}</ref> All 14 amino acids in the aromatic gorge are highly conserved across different species.<ref name="pmid8349597">{{cite journal | vauthors = Ordentlich A, Barak D, Kronman C, Flashner Y, Leitner M, Segall Y, Ariel N, Cohen S, Velan B, Shafferman A | title = Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket | journal = J. Biol. Chem. | volume = 268 | issue = 23 | pages = 17083–95 | date = August 1993 | pmid = 8349597 }} {{open access}}</ref> Among the aromatic amino acids, [[tryptophan]] 84 is critical and its substitution with [[alanine]] results in a 3000-fold decrease in reactivity.<ref>{{cite journal | vauthors = Tougu V | title = Acetylcholinesterase: Mechanism of Catalysis and Inhibition | journal = Current Medicinal Chemistry Central Nervous System Agents | volume = 1 | issue =  2| pages = 155–170 | year = 2001 | doi = 10.2174/1568015013358536 |url = https://www.researchgate.net/publication/233701777_Acetylcholinesterase_Mechanism_of_Catalysis_and_Inhibition/file/72e7e5163e39a2e539.pdf}} {{closed access}}</ref> The gorge penetrates halfway through the enzyme and is approximately 20 [[angstroms]] long.  The active site is located 4 angstroms from the bottom of the molecule.<ref>{{cite journal | vauthors = Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL | title = Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 90 | issue = 19 | pages = 9031–5 | year = 1993 | pmid = 8415649 | pmc = 47495 | doi = 10.1073/pnas.90.19.9031 | bibcode = 1993PNAS...90.9031H }}</ref>
Line 24: Line 26:
==Biological function==
==Biological function==


During [[neurotransmission]], ACh is released from the presynaptic neuron into the [[Synapse|synaptic]] cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic neuron and ACh is synthesized by combining with [[acetyl-CoA]] through the action of [[choline acetyltransferase]].<ref>{{cite journal | vauthors = Whittaker VP | title = The Contribution of Drugs and Toxins to Understanding of Cholinergic Function | journal = Trends in Physiological Sciences | volume = 11 | issue = 1 | pages = 8–13 | year = 1990 | pmid = 2408211 | doi = 10.1016/0165-6147(90)90034-6 }}</ref><ref>{{cite book | vauthors = Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO , White LE | title = Neuroscience | edition = 4th | year = 2008 | publisher = Sinauer Associates | isbn = 978-0-87893-697-7 | pages = 121–2 }}</ref>
During [[neurotransmission]], ACh is released from the presynaptic neuron into the [[Synapse|synaptic]] cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic neuron and ACh is synthesized by combining with [[acetyl-CoA]] through the action of [[choline acetyltransferase]].<ref>{{cite journal | vauthors = Whittaker VP | title = The Contribution of Drugs and Toxins to Understanding of Cholinergic Function | journal = Trends in Pharmacological Sciences | volume = 11 | issue = 1 | pages = 8–13 | year = 1990 | pmid = 2408211 | doi = 10.1016/0165-6147(90)90034-6 }}</ref><ref>{{cite book | vauthors = Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO , White LE | title = Neuroscience | edition = 4th | year = 2008 | publisher = Sinauer Associates | isbn = 978-0-87893-697-7 | pages = 121–2 }}</ref>


A [[cholinomimetic]] drug disrupts this process by acting as a cholinergic neurotransmitter that is impervious to acetylcholinesterase's lysing action.
A [[cholinomimetic]] drug disrupts this process by acting as a cholinergic neurotransmitter that is impervious to acetylcholinesterase's lysing action.
Line 34: Line 36:
[[File:AChe inhibitors pic.jpg|thumb|left|Mechanism of Inhibitors of AChE]]
[[File:AChe inhibitors pic.jpg|thumb|left|Mechanism of Inhibitors of AChE]]


Irreversible inhibitors of AChE may lead to muscular [[paralysis]], convulsions, [[bronchial]] constriction, and death by [[asphyxiation]].  [[Organophosphates]] (OP), esters of phosphoric acid, are a class of irreversible AChE inhibitors.<ref>{{cite web|title=National Pesticide Information Center-Diazinon Technical Fact Sheet|url=http://npic.orst.edu/factsheets/diazinontech.pdf|accessdate=24 February 2012}}</ref> Cleavage of OP by AChE leaves a phosphoryl group in the esteratic site, which is slow to be hydrolyzed (on the order of days) and can become [[covalently]] bound. Irreversible AChE inhibitors have been used in [[insecticides]]  (e.g., [[malathion]]) and nerve gases for chemical warfare (e.g., [[Sarin]] and [[Soman]]). [[Carbamates]], esters of N-methyl carbamic acid, are AChE inhibitors that hydrolyze in hours and have been used for medical purposes (e.g., [[physostigmine]] for the treatment of [[glaucoma]]). Reversible inhibitors occupy the esteratic site for short periods of time (seconds to minutes) and are used to treat of a range of central nervous system diseases. Tetrahydroaminoacridine (THA) and [[donepezil]] are FDA-approved to improve cognitive function in [[Alzheimer's disease]]. [[Rivastigmine]] is also used to treat Alzheimer's and [[Lewy body dementia]], and [[pyridostigmine]] bromide is used to treat [[myasthenia gravis]].<ref>{{cite web|title=Clinical Application: Acetylcholine and Alzheimer's Disease|url=http://web.williams.edu/imput/synapse/pages/IA5.html|accessdate=24 February 2012}}</ref><ref>{{cite book | last = Stoelting | first = R.K. | name-list-format = vanc | title= Anticholinesterase Drugs and Cholinergic Agonists", in Pharmacology and Physiology in Anesthetic Practice|year=1999|publisher=Lippincott-Raven|isbn=978-0-7817-5469-9|url=http://www.anesthesia2000.com/Autonomics/Cholinergics/Cholin2.htm}}</ref><ref>{{cite book | last = Taylor | first = P | name-list-format = vanc | title = The Pharmacologial Basis of Therapeutics|year=1996|publisher=THe McGraw-Hill Companies|isbn=978-0-07-146804-6|pages=161–174|url=http://nursingpharmacology.info/Autonomics/Cholinergics/Cholin1.htm|author2=Hardman, J.G |author3=Limbird, L.E |author4=Molinoff, P.B. |author5=Ruddon, R.W |author6=Gilman, A.G. |chapter=5: Autonomic Pharmacology: Cholinergic Drugs}}</ref><ref name="isbn0-07-146804-8">{{cite book | vauthors =  Blumenthal D,  Brunton L, Goodman LS,  Parker K, Gilman A, Lazo JS,  Buxton I | title = Goodman & Gilman's The pharmacological basis of therapeutics | publisher = McGraw-Hill | location = New York | year = 1996 | pages = 1634 | isbn = 978-0-07-146804-6 | chapter=5: Autonomic Pharmacology: Cholinergic Drugs }}</ref><ref>{{cite book | last = Drachman | first = D.B. | name-list-format = vanc | title=Harrison's Principles of Internal Medicine|year=1998|publisher=The McCraw-Hill Companies|isbn=978-0-07-020291-7|pages=2469–2472|edition=14|author2=Isselbacher, K.J. |author3=Braunwald, E. |author4=Wilson, J.D. |author5=Martin, J.B. |author6=Fauci, A.S. |author7=Kasper, D.L. }}</ref><ref>{{cite book | last = Raffe | first = RB | name-list-format =vanc | title = Autonomic and Somatic Nervous Systems in Netter's Illustrated Pharmacology|publisher=Elsevier Health Science|isbn=978-1-929007-60-8|pages=43}}</ref>
Irreversible inhibitors of AChE may lead to muscular [[paralysis]], convulsions, [[bronchial]] constriction, and death by [[asphyxiation]].  [[Organophosphates]] (OP), esters of phosphoric acid, are a class of irreversible AChE inhibitors.<ref>{{cite web|title=National Pesticide Information Center-Diazinon Technical Fact Sheet|url=http://npic.orst.edu/factsheets/diazinontech.pdf|accessdate=24 February 2012}}</ref> Cleavage of OP by AChE leaves a phosphoryl group in the esteratic site, which is slow to be hydrolyzed (on the order of days) and can become [[covalently]] bound. Irreversible AChE inhibitors have been used in [[insecticides]]  (e.g., [[malathion]]) and nerve gases for chemical warfare (e.g., [[Sarin]] and [[Soman]]). [[Carbamates]], esters of N-methyl carbamic acid, are AChE inhibitors that hydrolyze in hours and have been used for medical purposes (e.g., [[physostigmine]] for the treatment of [[glaucoma]]). Reversible inhibitors occupy the esteratic site for short periods of time (seconds to minutes) and are used to treat of a range of central nervous system diseases. Tetrahydroaminoacridine (THA) and [[donepezil]] are FDA-approved to improve cognitive function in [[Alzheimer's disease]]. [[Rivastigmine]] is also used to treat Alzheimer's and [[Lewy body dementia]], and [[pyridostigmine]] bromide is used to treat [[myasthenia gravis]].<ref>{{cite web|title=Clinical Application: Acetylcholine and Alzheimer's Disease|url=http://web.williams.edu/imput/synapse/pages/IA5.html|accessdate=24 February 2012}}</ref><ref>{{cite book | vauthors = Stoelting RK | title= Anticholinesterase Drugs and Cholinergic Agonists", in Pharmacology and Physiology in Anesthetic Practice|year=1999|publisher=Lippincott-Raven|isbn=978-0-7817-5469-9|url=http://www.anesthesia2000.com/Autonomics/Cholinergics/Cholin2.htm}}</ref><ref>{{cite book | vauthors = Taylor P, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG | title = The Pharmacologial Basis of Therapeutics|year=1996|publisher=THe McGraw-Hill Companies|isbn=978-0-07-146804-6|pages=161–174|url=http://nursingpharmacology.info/Autonomics/Cholinergics/Cholin1.htm |chapter=5: Autonomic Pharmacology: Cholinergic Drugs}}</ref><ref name="isbn0-07-146804-8">{{cite book | vauthors =  Blumenthal D,  Brunton L, Goodman LS,  Parker K, Gilman A, Lazo JS,  Buxton I | title = Goodman & Gilman's The pharmacological basis of therapeutics | publisher = McGraw-Hill | location = New York | year = 1996 | pages = 1634 | isbn = 978-0-07-146804-6 | chapter=5: Autonomic Pharmacology: Cholinergic Drugs }}</ref><ref>{{cite book | vauthors = Drachman DB, Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL | title=Harrison's Principles of Internal Medicine|year=1998|publisher=The McCraw-Hill Companies|isbn=978-0-07-020291-7|pages=2469–2472|edition=14 }}</ref><ref>{{cite book | vauthors = Raffe RB | title = Autonomic and Somatic Nervous Systems in Netter's Illustrated Pharmacology|publisher=Elsevier Health Science|isbn=978-1-929007-60-8|pages=43}}</ref>
   
   
An endogenous inhibitor of AChE in neurons is [[Mir-132 microRNA]], which may limit inflammation in the brain by silencing the expression of this protein and allowing ACh to act in an anti-inflammatory capacity.<ref name="pmid20005135">{{cite journal | vauthors = Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H | title = MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase | journal = Immunity | volume = 31 | issue = 6 | pages = 965–73 | year = 2009 | pmid = 20005135 | doi = 10.1016/j.immuni.2009.09.019 }}</ref>
An endogenous inhibitor of AChE in neurons is [[Mir-132 microRNA]], which may limit inflammation in the brain by silencing the expression of this protein and allowing ACh to act in an anti-inflammatory capacity.<ref name="pmid20005135">{{cite journal | vauthors = Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H | title = MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase | journal = Immunity | volume = 31 | issue = 6 | pages = 965–73 | year = 2009 | pmid = 20005135 | doi = 10.1016/j.immuni.2009.09.019 }}</ref>
Line 48: Line 50:
== AChE gene ==
== AChE gene ==


In mammals, acetylcholinesterase is encoded by a single AChE gene while some invertebrates have multiple acetylcholinesterase genes. Diversity in the transcribed products from the sole mammalian gene arises from alternative [[alternative splicing|mRNA splicing]] and [[post-translational]] associations of catalytic and structural subunits. There are three known forms: T (tail), R (read through), and H(hydrophobic).<ref name="pmid18541228">{{cite journal | vauthors = Massoulié J, Perrier N, Noureddine H, Liang D, Bon S | title = Old and new questions about cholinesterases | journal = Chem Biol Interact | volume = 175 | issue = 1–3 | pages = 30–44 | year = 2008 | pmid = 18541228 | doi = 10.1016/j.cbi.2008.04.039 }}</ref>
In mammals, acetylcholinesterase is encoded by a single AChE gene while some invertebrates have multiple acetylcholinesterase genes. Note higher vertebrates also encode a closely related paralog BCHE (butyrylcholinesterase) with 50% amino acid identity to ACHE <ref>Johnson G, Moore SW.,  Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. 2012 Neurochem Int., 16, p.783-797  {{doi| 10.1016/j.neuint.2012.06.016}}</ref>. Diversity in the transcribed products from the sole mammalian gene arises from alternative [[alternative splicing|mRNA splicing]] and [[post-translational]] associations of catalytic and structural subunits. There are three known forms: T (tail), R (read through), and H(hydrophobic).<ref name="pmid18541228">{{cite journal | vauthors = Massoulié J, Perrier N, Noureddine H, Liang D, Bon S | title = Old and new questions about cholinesterases | journal = Chem Biol Interact | volume = 175 | issue = 1–3 | pages = 30–44 | year = 2008 | pmid = 18541228 | doi = 10.1016/j.cbi.2008.04.039 }}</ref>


===AChE<sub>T</sub>===
===AChE<sub>T</sub>===
Line 63: Line 65:


== Inhibitors ==
== Inhibitors ==
For [[acetylcholine esterase]] (AChE), '''reversible inhibitors''' are those that do not irreversibly bond to and decactivate AChE.<ref>{{cite journal|last1=Millary|first1=CB|last2=Kryger|first2=G|year=199|title=Crystal structures of aged phosphorylated acetylcholinesterase: nerve agent reaction products at the atomic level|journal=Biochemistry|publisher=Weizmann Institute of Science|volume=38|issue=22|pages=7032–7039|doi=10.1021/bi982678l|pmid=10353814}}</ref> Drugs that reversibly inhibit acetylcholine esterase are being explored as treatments for [[Alzheimer's disease]] and [[myasthenia gravis]], among others. Examples include [[tacrine]] and [[donepezil]].<ref>{{Cite book|url=|title=A Primer of Drug Action|last=Julien|first=Robert|date=|publisher=Worth Publishers|isbn=978-1-4292-0679-2|edition=Eleventh|series=|volume=|location=|pages=50|doi=|jfm=|mr=|zbl=|authorlink=|coauthors=}}</ref>
For [[acetylcholine esterase]] (AChE), '''reversible inhibitors''' are those that do not irreversibly bond to and deactivate AChE.<ref name="Millard_1999">{{cite journal | vauthors = Millard CB, Kryger G, Ordentlich A, Greenblatt HM, Harel M, Raves ML, Segall Y, Barak D, Shafferman A, Silman I, Sussman JL | title = Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level | journal = Biochemistry | volume = 38 | issue = 22 | pages = 7032–9 | date = June 1999 | pmid = 10353814 | doi = 10.1021/bi982678l }}</ref> Drugs that reversibly inhibit acetylcholine esterase are being explored as treatments for [[Alzheimer's disease]] and [[myasthenia gravis]], among others. Examples include [[tacrine]] and [[donepezil]].<ref>{{cite book | title = A Primer of Drug Action | first1 = Robert M. | last1 = Julien | first2 = Claire D. | last2 = Advokat | first3 = Joseph E. | last3 = Comaty | name-list-format = vanc | publisher = Worth Publishers | isbn = 978-1-4292-0679-2 | edition = Eleventh | pages = 50 }}</ref>


== See also ==
== See also ==
*[[Acetylcholinesterase inhibitor]]
* {{Portal-inline|Molecular and Cellular Biology}}
*[[Cholinesterase]]s
* [[Acetylcholinesterase inhibitor]]
* [[Cholinesterase]]s


== References ==
== References ==
{{reflist | 35em}}
{{reflist|32em}}


== Further reading ==
== Further reading ==
Line 103: Line 106:
* {{Proteopedia|AChE_inhibitors_and_substrates_(Part_II)}}
* {{Proteopedia|AChE_inhibitors_and_substrates_(Part_II)}}
* {{Proteopedia|AChE_bivalent_inhibitors AChE bivalent inhibitors}}
* {{Proteopedia|AChE_bivalent_inhibitors AChE bivalent inhibitors}}
*[http://www.ebi.ac.uk/pdbe/quips?story=AChE Acetylcholinesterase: A gorge-ous enzyme] – PDBe
* [http://www.ebi.ac.uk/pdbe/quips?story=AChE Acetylcholinesterase: A gorge-ous enzyme]—PDBe
*[http://pdb101.rcsb.org/motm/54 Acetylcholinesterase] – RCSB PDB
* [http://pdb101.rcsb.org/motm/54 Acetylcholinesterase]—RCSB PDB
* {{UCSC gene info|ACHE}}
* {{UCSC gene info|ACHE}}


Line 113: Line 116:
{{Acetylcholine metabolism and transport modulators}}
{{Acetylcholine metabolism and transport modulators}}
{{Authority control}}
{{Authority control}}
{{Portal bar|Molecular and Cellular Biology|border=no}}


[[Category:Acetylcholine]]
[[Category:Acetylcholine]]
[[Category:EC 3.1.1]]
[[Category:EC 3.1.1]]

Latest revision as of 04:43, 21 September 2018

acetylcholinesterase
File:The reaction catalyzed by acetylcholinesterase.tif
Acetylcholinesterase catalyzes the hydrolysis of acetylcholine to acetate ion and choline
Identifiers
EC number3.1.1.7
CAS number9000-81-1
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Acetylcholinesterase (HGNC symbol ACHE; EC 3.1.1.7), also known as AChE or acetylhydrolase, is the primary cholinesterase in the body. It is an enzyme that catalyzes the breakdown of acetylcholine and of some other choline esters that function as neurotransmitters. AChE is found at mainly neuromuscular junctions and in chemical synapses of the cholinergic type, where its activity serves to terminate synaptic transmission. It belongs to carboxylesterase family of enzymes. It is the primary target of inhibition by organophosphorus compounds such as nerve agents and pesticides.

Enzyme structure and mechanism

File:AChe mechanism of action.jpg
AChe mechanism of action[1]

AChE is a hydrolase that hydrolyzes choline esters. It has a very high catalytic activity—each molecule of AChE degrades about 25000 molecules of acetylcholine (ACh) per second, approaching the limit allowed by diffusion of the substrate.[2][3] The active site of AChE comprises 2 subsites—the anionic site and the esteratic subsite. The structure and mechanism of action of AChE have been elucidated from the crystal structure of the enzyme.[4][5]

The anionic subsite accommodates the positive quaternary amine of acetylcholine as well as other cationic substrates and inhibitors. The cationic substrates are not bound by a negatively charged amino acid in the anionic site, but by interaction of 14 aromatic residues that line the gorge leading to the active site.[6][7][8] All 14 amino acids in the aromatic gorge are highly conserved across different species.[9] Among the aromatic amino acids, tryptophan 84 is critical and its substitution with alanine results in a 3000-fold decrease in reactivity.[10] The gorge penetrates halfway through the enzyme and is approximately 20 angstroms long. The active site is located 4 angstroms from the bottom of the molecule.[11]

The esteratic subsite, where acetylcholine is hydrolyzed to acetate and choline, contains the catalytic triad of three amino acids: serine 200, histidine 440 and glutamate 327. These three amino acids are similar to the triad in other serine proteases except that the glutamate is the third member rather than aspartate. Moreover, the triad is of opposite chirality to that of other proteases.[12] The hydrolysis reaction of the carboxyl ester leads to the formation of an acyl-enzyme and free choline. Then, the acyl-enzyme undergoes nucleophilic attack by a water molecule, assisted by the histidine 440 group, liberating acetic acid and regenerating the free enzyme.[13][14]

Biological function

During neurotransmission, ACh is released from the presynaptic neuron into the synaptic cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic neuron and ACh is synthesized by combining with acetyl-CoA through the action of choline acetyltransferase.[15][16]

A cholinomimetic drug disrupts this process by acting as a cholinergic neurotransmitter that is impervious to acetylcholinesterase's lysing action.

Disease relevance

For a cholinergic neuron to receive another impulse, ACh must be released from the ACh receptor. This occurs only when the concentration of ACh in the synaptic cleft is very low. Inhibition of AChE leads to accumulation of ACh in the synaptic cleft and results in impeded neurotransmission.[17]

File:AChe inhibitors pic.jpg
Mechanism of Inhibitors of AChE

Irreversible inhibitors of AChE may lead to muscular paralysis, convulsions, bronchial constriction, and death by asphyxiation. Organophosphates (OP), esters of phosphoric acid, are a class of irreversible AChE inhibitors.[18] Cleavage of OP by AChE leaves a phosphoryl group in the esteratic site, which is slow to be hydrolyzed (on the order of days) and can become covalently bound. Irreversible AChE inhibitors have been used in insecticides (e.g., malathion) and nerve gases for chemical warfare (e.g., Sarin and Soman). Carbamates, esters of N-methyl carbamic acid, are AChE inhibitors that hydrolyze in hours and have been used for medical purposes (e.g., physostigmine for the treatment of glaucoma). Reversible inhibitors occupy the esteratic site for short periods of time (seconds to minutes) and are used to treat of a range of central nervous system diseases. Tetrahydroaminoacridine (THA) and donepezil are FDA-approved to improve cognitive function in Alzheimer's disease. Rivastigmine is also used to treat Alzheimer's and Lewy body dementia, and pyridostigmine bromide is used to treat myasthenia gravis.[19][20][21][22][23][24]

An endogenous inhibitor of AChE in neurons is Mir-132 microRNA, which may limit inflammation in the brain by silencing the expression of this protein and allowing ACh to act in an anti-inflammatory capacity.[25]

It has also been shown that the main active ingredient in cannabis, tetrahydrocannabinol, is a competitive inhibitor of acetylcholinesterase.[26]

Distribution

AChE is found in many types of conducting tissue: nerve and muscle, central and peripheral tissues, motor and sensory fibers, and cholinergic and noncholinergic fibers. The activity of AChE is higher in motor neurons than in sensory neurons.[27][28][29]

Acetylcholinesterase is also found on the red blood cell membranes, where different forms constitute the Yt blood group antigens.[30] Acetylcholinesterase exists in multiple molecular forms, which possess similar catalytic properties, but differ in their oligomeric assembly and mode of attachment to the cell surface.

AChE gene

In mammals, acetylcholinesterase is encoded by a single AChE gene while some invertebrates have multiple acetylcholinesterase genes. Note higher vertebrates also encode a closely related paralog BCHE (butyrylcholinesterase) with 50% amino acid identity to ACHE [31]. Diversity in the transcribed products from the sole mammalian gene arises from alternative mRNA splicing and post-translational associations of catalytic and structural subunits. There are three known forms: T (tail), R (read through), and H(hydrophobic).[32]

AChET

The major form of acetylcholinesterase found in brain, muscle, and other tissues, known as is the hydrophilic species, which forms disulfide-linked oligomers with collagenous, or lipid-containing structural subunits. In the neuromuscular junctions AChE expresses in asymmetric form which associates with ColQ or subunit. In the central nervous system it is associated with PRiMA which stands for Proline Rich Membrane anchor to form symmetric form. In either case, the ColQ or PRiMA anchor serves to maintain the enzyme in the intercellular junction, ColQ for the neuromuscular junction and PRiMA for synapses.

AChEH

The other, alternatively spliced form expressed primarily in the erythroid tissues, differs at the C-terminus, and contains a cleavable hydrophobic peptide with a PI-anchor site. It associates with membranes through the phosphoinositide (PI) moieties added post-translationally.[33]

AChER

The third type has, so far, only been found in Torpedo sp. and mice although it is hypothesized in other species. It is thought to be involved in the stress response and, possibly, inflammation.[34]

Nomenclature

The nomenclatural variations of ACHE and of cholinesterases generally are discussed at Cholinesterase § Types and nomenclature.

Inhibitors

For acetylcholine esterase (AChE), reversible inhibitors are those that do not irreversibly bond to and deactivate AChE.[35] Drugs that reversibly inhibit acetylcholine esterase are being explored as treatments for Alzheimer's disease and myasthenia gravis, among others. Examples include tacrine and donepezil.[36]

See also

References

  1. Katzung BG (2001). Basic and clinical pharmacology:Introduction to autonomic pharmacology (8 ed.). The McGraw Hill Companies. pp. 75–91. ISBN 978-0-07-160405-5.
  2. Quinn DM (1987). "Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states". Chemical Reviews. 87 (5): 955–79. doi:10.1021/cr00081a005.
  3. Taylor P, Radić Z (1994). "The cholinesterases: from genes to proteins". Annual Review of Pharmacology and Toxicology. 34: 281–320. doi:10.1146/annurev.pa.34.040194.001433. PMID 8042853.
  4. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I (August 1991). "Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein". Science. 253 (5022): 872–9. Bibcode:1991Sci...253..872S. doi:10.1126/science.1678899. PMID 1678899.
  5. Sussman JL, Harel M, Silman I (June 1993). "Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs". Chem. Biol. Interact. 87 (1–3): 187–97. doi:10.1016/0009-2797(93)90042-W. PMID 8343975.
  6. Radić Z, Gibney G, Kawamoto S, MacPhee-Quigley K, Bongiorno C, Taylor P (October 1992). "Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants". Biochemistry. 31 (40): 9760–7. doi:10.1021/bi00155a032. PMID 1356436.
  7. Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, Shafferman A (February 1995). "Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase". J. Biol. Chem. 270 (5): 2082–91. doi:10.1074/jbc.270.5.2082. PMID 7836436.
  8. Ariel N, Ordentlich A, Barak D, Bino T, Velan B, Shafferman A (October 1998). "The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors". Biochem. J. 335 (1): 95–102. PMC 1219756. PMID 9742217. open access publication – free to read
  9. Ordentlich A, Barak D, Kronman C, Flashner Y, Leitner M, Segall Y, Ariel N, Cohen S, Velan B, Shafferman A (August 1993). "Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket". J. Biol. Chem. 268 (23): 17083–95. PMID 8349597. open access publication – free to read
  10. Tougu V (2001). "Acetylcholinesterase: Mechanism of Catalysis and Inhibition" (PDF). Current Medicinal Chemistry Central Nervous System Agents. 1 (2): 155–170. doi:10.2174/1568015013358536. closed access publication – behind paywall
  11. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL (1993). "Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase". Proceedings of the National Academy of Sciences of the United States of America. 90 (19): 9031–5. Bibcode:1993PNAS...90.9031H. doi:10.1073/pnas.90.19.9031. PMC 47495. PMID 8415649.
  12. Tripathi A (October 2008). "Acetylcholinsterase: A Versatile Enzyme of Nervous System". Annals of Neurosciences. 15 (4): 106–111. doi:10.5214/ans.0972.7531.2008.150403.
  13. Pauling L (1946). "Molecular Architecture and Biological Reactions" (PDF). Chemical & Engineering News. 24 (10): 1375–1377. doi:10.1021/cen-v024n010.p1375.
  14. Fersht A (1985). Enzyme structure and mechanism. San Francisco: W.H. Freeman. p. 14. ISBN 0-7167-1614-3.
  15. Whittaker VP (1990). "The Contribution of Drugs and Toxins to Understanding of Cholinergic Function". Trends in Pharmacological Sciences. 11 (1): 8–13. doi:10.1016/0165-6147(90)90034-6. PMID 2408211.
  16. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO, White LE (2008). Neuroscience (4th ed.). Sinauer Associates. pp. 121–2. ISBN 978-0-87893-697-7.
  17. [citation needed]
  18. "National Pesticide Information Center-Diazinon Technical Fact Sheet" (PDF). Retrieved 24 February 2012.
  19. "Clinical Application: Acetylcholine and Alzheimer's Disease". Retrieved 24 February 2012.
  20. Stoelting RK (1999). Anticholinesterase Drugs and Cholinergic Agonists", in Pharmacology and Physiology in Anesthetic Practice. Lippincott-Raven. ISBN 978-0-7817-5469-9.
  21. Taylor P, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (1996). "5: Autonomic Pharmacology: Cholinergic Drugs". The Pharmacologial Basis of Therapeutics. THe McGraw-Hill Companies. pp. 161–174. ISBN 978-0-07-146804-6.
  22. Blumenthal D, Brunton L, Goodman LS, Parker K, Gilman A, Lazo JS, Buxton I (1996). "5: Autonomic Pharmacology: Cholinergic Drugs". Goodman & Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill. p. 1634. ISBN 978-0-07-146804-6.
  23. Drachman DB, Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (1998). Harrison's Principles of Internal Medicine (14 ed.). The McCraw-Hill Companies. pp. 2469–2472. ISBN 978-0-07-020291-7.
  24. Raffe RB. Autonomic and Somatic Nervous Systems in Netter's Illustrated Pharmacology. Elsevier Health Science. p. 43. ISBN 978-1-929007-60-8.
  25. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H (2009). "MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase". Immunity. 31 (6): 965–73. doi:10.1016/j.immuni.2009.09.019. PMID 20005135.
  26. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD (2006). "A molecular link between the active component of marijuana and Alzheimer's disease pathology". Mol Pharm. 3 (6): 773–7. doi:10.1021/mp060066m. PMC 2562334. PMID 17140265.
  27. Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM (July 1993). "Molecular and cellular biology of cholinesterases". Progress in Neurobiology. 41 (1): 31–91. doi:10.1016/0301-0082(93)90040-Y. PMID 8321908.
  28. Chacko LW, Cerf JA (1960). "Histochemical localization of cholinesterase in the amphibian spinal cord and alterations following ventral root section". Journal of Anatomy. 94 (Pt 1): 74–81. PMC 1244416. PMID 13808985.
  29. Koelle GB (1954). "The histochemical localization of cholinesterases in the central nervous system of the rat". Journal of Comparative Anatomy. 100 (1): 211–35. doi:10.1002/cne.901000108. PMID 13130712.
  30. Bartels CF, Zelinski T, Lockridge O (May 1993). "Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism". Am. J. Hum. Genet. 52 (5): 928–36. PMC 1682033. PMID 8488842.
  31. Johnson G, Moore SW., Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. 2012 Neurochem Int., 16, p.783-797 doi: 10.1016/j.neuint.2012.06.016
  32. Massoulié J, Perrier N, Noureddine H, Liang D, Bon S (2008). "Old and new questions about cholinesterases". Chem Biol Interact. 175 (1–3): 30–44. doi:10.1016/j.cbi.2008.04.039. PMID 18541228.
  33. "Entrez Gene: ACHE acetylcholinesterase (Yt blood group)".
  34. Dori A, Ifergane G, Saar-Levy T, Bersudsky M, Mor I, Soreq H, Wirguin I (2007). "Readthrough acetylcholinesterase in inflammation-associated neuropathies". Life Sci. 80 (24–25): 2369–74. doi:10.1016/j.lfs.2007.02.011. PMID 17379257.
  35. Millard CB, Kryger G, Ordentlich A, Greenblatt HM, Harel M, Raves ML, Segall Y, Barak D, Shafferman A, Silman I, Sussman JL (June 1999). "Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level". Biochemistry. 38 (22): 7032–9. doi:10.1021/bi982678l. PMID 10353814.
  36. Julien RM, Advokat CD, Comaty JE. A Primer of Drug Action (Eleventh ed.). Worth Publishers. p. 50. ISBN 978-1-4292-0679-2.

Further reading

External links

Lua error in Module:Authority_control at line 788: attempt to index field 'wikibase' (a nil value).